Manufacturer
UNICHEM LABS LTD
Contents
Lansoprazole
Indication
Reflux oesophagitis, Gastro-oesophageal reflux disease, NSAID-associated ulceration, Zollinger-Ellison syndrome, Eradication of H. pylori associated with peptic ulcer disease, Prophylaxis of NSAID-induced ulcers, Peptic ulcer.
Instruction
Should be taken on an empty stomach.
Drug interaction
May decrease plasma concentrations of rilpivirine, atazanavir and nelfinavir. Increased INR and prothrombin time with warfarin. May diminish the therapeutic effect of clopidogrel. May increase exposure of digoxins. May reduce absorption of ketoconazole and itraconazole. May increase risk of hypomagnesaemia with diuretics. May increase plasma concentrations of methotrexate and tacrolimus. May reduce serum concentration of theophylline. Reduced bioavailability with sucralfate and antacids. Increased plasma concentration with CYP2C19 inhibitor (e.g. fluvoxamine). Reduced serum levels with CYP2C19 and CYP3A4 inducers (e.g. rifampicin).
Malaysia
